Who is sponsoring NCT03348696?

NCT03348696 is sponsored by Ottawa Hospital Research Institute.

What drugs are being tested in NCT03348696?

Interventions in NCT03348696: Dexamethasone tapering dose, Dexamethasone physician choice.

What condition does NCT03348696 study?

NCT03348696 studies Early-stage Breast Cancer, Pain Syndrome.

Is NCT03348696 still recruiting?

NCT03348696 is currently completed. Last updated 9 January 2020.

Last reviewed 2020-01-09 · How we verify

NCT03348696: REaCT-TAPS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients

Completed Phase 4 Last updated 9 January 2020

What this trial tests

Phase 4 trial testing Dexamethasone tapering dose in Early-stage Breast Cancer in 124 participants. Completed in 2 April 2019.

Timeline

28 February 2018

Primary endpoint
2 April 2019

2 April 2019

Quick facts

Lead sponsor	Ottawa Hospital Research Institute
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	124
Start date	28 February 2018
Primary completion	2 April 2019
Estimated completion	2 April 2019
Sites	2 locations across Canada

Drugs / interventions tested

Dexamethasone tapering dose — full drug profile →
Dexamethasone physician choice — full drug profile →

Conditions studied

Early-stage Breast Cancer — all drugs for Early-stage Breast Cancer →
Pain Syndrome — all drugs for Pain Syndrome →

Sponsor

Ottawa Hospital Research Institute

Who can join

19 and older, any sex, with Early-stage Breast Cancer or Pain Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The REaCT TAPS clinical trial will compare a tapering dose of dexamethasone to other standards of care on the presence of taxane-associated pain syndrome (TAPS) in early stage breast cancer.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Inflammation and tumor progression: signaling pathways and targeted intervention.
Zhao H, Wu L, Yan G, Chen Y, et al · · 2021 · cited 1932× · PMID 34248142 · DOI 10.1038/s41392-021-00658-5
Tumor biomarkers for diagnosis, prognosis and targeted therapy.
Zhou Y, Tao L, Qiu J, Xu J, et al · · 2024 · cited 379× · PMID 38763973 · DOI 10.1038/s41392-024-01823-2
A prospective multi-centre, randomized study comparing the addition of tapering dexamethasone to other standard of care therapies for taxane-associated pain syndrome (TAPS) in breast cancer patients.
Clemons M, Simos D, Sienkiewicz M, Ng T, et al · · 2021 · cited 10× · PMID 33742240 · DOI 10.1007/s00520-021-06142-8
The Rethinking Clinical Trials (REaCT) Program: A Pragmatic Research Strategy to Improve Cancer Care for Patients, Caregivers, and Healthcare Systems.
Savard MF, Clemons M, McGee SF. · · 2025 · cited 1× · PMID 41002554 · DOI 10.3390/curroncol32090484

Verify or expand the search:

Other recruiting trials for Early-stage Breast Cancer

Currently open trials in the same condition.

NCT06215469 — Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads) · NA · recruiting
NCT06144944 — Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer · Phase 3 · active not recruiting
NCT06001762 — TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer · Phase 2 · active not recruiting
NCT05957068 — Breast Cancer Exercise Intervention Study · NA · recruiting
NCT06035016 — Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer · recruiting

Other Ottawa Hospital Research Institute trials

Trials by the same sponsor.

NCT07464080 — Advanced Brain Imaging-TKA (fMRI-TKA) · NA · recruiting
NCT07171567 — Vacuum Therapy for the Treatment of Penile Numbness/Sensory Changes · EARLY_PHASE1 · recruiting
NCT07058025 — Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants · Phase 2 · not yet recruiting
NCT07177833 — Title Fractioned CO2 Laser in the Treatment of Chronic Phase Peyronie's Disease · Phase 1 · recruiting
NCT06929767 — Do Blood Tests Help to Decide Which Patients With Flares of Chronic Obstructive Pulmonary Disease (COPD) Need Antibiotic · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03348696 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ottawa Hospital Research Institute
Last refreshed: 9 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03348696.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing